DOCSLIB.ORG

Clinical Guidelines for Organ Transplantation from Deceased Donors Version 1.5 – April 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clinical Guidelines for Organ Transplantation from Deceased Donors Version 1.5 – April 2021 The Transplantation Society of Australia and New Zealand Clinical Guidelines for Organ Transplantation from Deceased Donors Version 1.5 – April 2021 Produced in partnership with Version 1.0 of the Clinical Guidelines for Organ Transplantation from Deceased Donors (the Clinical Guidelines) was released in April 2016. Updates were made in May 2017 (Version 1.1), December 2018 (Version 1.2), May 2019 (Version 1.3), and July 2020 (Version 1.4). The current document, Version 1.5 (April 2021), replaces these previous versions of the Clinical Guidelines. Version control Version # Changes made Approved by Date 1.5 Updated advice related COVID-19 (section 2.3.2.1). Australasian Transplant 28 April 2021 Addition of advice in the event of reactive screening antibody Coordinators Association results (section 2.3.2.9). (ATCA), Transplant Society of Australia and New Zealand Addition of section 2.5 on Risks related to other donor (TSANZ) and Organ and conditions. Tissue Authority (OTA). Updates relating to the Australian and New Zealand paired Kidney Exchange Program (ANZKX) (sections 5.2.5 and 5.4.4). 1.4 Chapter 11 (Paediatric Donors) was added to the Guidelines, Paediatric Donor Working 24 July 2020 providing organ-specific advice on acceptability and allocation Group. Australasian of organs from paediatric donors. Each of the organ- Transplant Coordinators specific chapters in Part B were updated to reflect the new Association (ATCA), recommendations for paediatric donors. Transplant Society of Australia and New Zealand Addition of advice on COVID-19 screening in deceased (TSANZ) and Organ and donors. Tissue Authority (OTA) 1.3 Broad revisions to section 2.3 (Donor assessment) and Australasian Transplant 31 May 2019 section 2.4 (Donor transmitted infectious disease). Coordinators Association (ATCA), Transplant Society of Addition of Appendix I: Summary of recommendations for Australia and New Zealand infectious disease screening in deceased donors (TSANZ) and Organ and Tissue Authority (OTA) References to donor and transplant registry statistics have been updated throughout to reflect the most up-to-date data. Changes to Chapter 4 (Heart): removal of the criterion of at least 10 years expected post-transplant survival (section 4.2); clarification of acceptable duration of warm ischaemia time (section 4.4.1); clarification of policy regarding HCV NAT- positive donors (section 4.7) Changes to Chapter 6 (Liver): updates to Section 6.4.1 ‘Use of HCV infected livers into HCV negative recipients’ 1.2 Changes to Chapter 5 (Kidney): Australasian Transplant 17 December Coordinators Association 2018 Rewording of the 80% five-year survival criterion for wait- (ATCA), Transplant Society of listing eligibility. This now states that “significant benefit” is Australia and New Zealand required from transplantation under section 5.1. (TSANZ) and Organ and Tissue Authority (OTA) An adjustment to the rules surrounding return of deceased donor waiting time in the event of a failed live donor transplant within 12 months under section 5.2. Removal of the 12-month waiting period for paediatric bonus score to be applied to section 5.2.4. 1.1 ’Use of HCV infected donor livers into HCV negative Australasian Transplant 17 May 2017 recipients’ has been added under section 6.4 on page 64. Coordinators Association Minor consequential amendments to Recipient Eligibility in (ATCA), Transplant Society of Section 1 and Organ Donor Eligibility in Section 2 have also Australia and New Zealand been made. (TSANZ) and Organ and Tissue Authority (OTA) April 2021 version 1.5 ii Disclaimer The information contained in this document is for general information only. It is designed to be educational, and is not intended to be—and is not—a complete or definitive statement on any area of medical practice or procedure. The Transplantation Society of Australia and New Zealand, its directors, and other officers make no express or implied warranties as to the suitability for a particular purpose or otherwise of the information included in this document. Rapid advances in medicine may cause information contained in this document to become out-dated or subject to debate. Readers of this document who are not medical practitioners qualified in the field should seek further professional advice before any action is taken in relation to the matters described or referred to in the document. April 2021 version 1.5 iii Table of contents Disclaimer iii Introduction vi Part A General issues related to recipient eligibility and donor assessment viii 1 Recipient Eligibility 1 1.1 Referral 1 1.2 Assessment for eligibility 1 1.3 Consent 2 1.4 Assessment and wait-listing 3 1.5 Appeals 3 1.6 Ongoing review 4 1.7 Retransplantation 4 2 Organ donor eligibility 6 2.1 The organ donation process 6 2.2 Deceased donor and organ assessment 7 2.3 Risk of donor transmitted infectious disease 12 2.4 Risk of donor transmitted malignancy 33 2.5 Risks related to other donor conditions 36 2.6 Organ distribution and allocation 38 2.7 Vigilance and Surveillance 39 3 Auditing and Monitoring 46 3.1 TSANZ Advisory Committee Audits 46 3.2 ATCA/TSANZ National Organ Allocation, Organ Rotation, Urgent Listing, Auditing Process 46 3.3 Data collection 46 3.4 Governance 47 Part B Organ-specific guidelines 48 4 Heart 49 4.1 Preamble 49 4.2 Recipient eligibility criteria 49 4.3 Waiting list management 53 4.4 Donor assessment 54 4.5 Allocation 56 4.6 Multi-organ transplantation 57 4.7 Emerging Issues 58 5 Kidney 61 5.1 Recipient eligibility criteria 61 5.2 Waiting list management 63 5.3 Donor assessment 65 5.4 Allocation: Australia 67 5.5 Allocation: New Zealand 71 5.6 Multi-organ transplantation 72 5.7 Emerging Issues 72 6 Liver 75 6.1 Preamble 75 6.2 Recipient eligibility criteria 76 6.3 Waiting list management 80 6.4 Donor assessment 82 6.5 Allocation 85 6.6 Multi organ transplantation 87 6.7 Emerging issues 88 April 2021 version 1.5 iv 7 Lung 90 7.1 Preamble 90 7.2 Recipient eligibility criteria 90 7.3 Waiting list management 92 7.4 Donor assessment 92 7.5 Allocation 93 7.6 Multi-organ transplantation 95 8 Pancreas and Islet 97 8.1 Preamble 97 8.2 Recipient eligibility criteria 97 8.3 Waiting list management 100 8.4 Donor assessment 101 8.5 Allocation 102 9 Intestine 105 9.1 Preamble 105 9.2 Parenteral Nutrition 106 9.3 Intestinal transplantation in Australia 106 9.4 Recipient eligibility 107 9.5 Donor assessment 110 9.6 Allocation 111 9.7 Multi-visceral intestinal allocation versus liver-pancreas allocation 111 10 Vascularised composite allotransplantation 113 10.1 Preamble 113 10.2 Recipient eligibility criteria: hand transplantation 113 10.3 Recipient eligibility criteria: face transplantation 115 10.4 Donor Assessment 116 10.5 Allocation of VCA organs 116 10.6 Multi-organ transplantation 117 10.7 Emerging Issues 117 Part C Special donor groups 119 11 Paediatric donors 120 11.1 Paediatric donor eligibility 120 11.2 Paediatric kidney donation and allocation 120 11.3 Paediatric liver and intestinal donation and allocation 121 11.4 Paediatric lung donation and allocation 121 11.5 Paediatric heart donation and allocation 122 11.6 Paediatric pancreas donation and allocation 122 Appendices 123 Appendix A 124 Appendix B 125 Appendix C 128 Appendix D 131 Appendix E 132 Appendix F 134 Appendix G 135 Appendix H 136 Appendix I 139 April 2021 version 1.5 v Introduction Organ transplantation is a highly effective treatment for advanced organ failure that relies on the donation of organs from living or deceased persons. The focus of this document is on the transplantation of solid organs donated from deceased persons. Currently, the number of patients who might potentially benefit from transplantation is far greater than the number of organs donated. For this reason, organ transplantation is offered primarily to patients who have end-stage organ disease and—with the exception of kidney transplantation—who have exhausted all alternative treatment options. Furthermore, transplantation is offered only to patients who have a reasonable prospect of achieving an acceptably good quality and duration of life after transplantation. Decision-making regarding the allocation and transplantation of donated organs seeks to balance the needs of individual patients against the need to maximise the overall benefit to the community from this scarce and valuable resource. The Transplantation Society of Australia and New Zealand (TSANZ) is the body responsible for developing eligibility criteria for organ transplantation and protocols for the allocation of deceased donor organs to wait-listed patients. Specifically, TSANZ is funded by the Australian Government’s Organ and Tissue Authority to maintain: 1. Current, nationally uniform eligibility criteria to ensure that there are equitable and transparent criteria by which patients are listed for organ transplantation, and 2. Current, nationally uniform allocation protocols to ensure consistency in the criteria by which donated organs are allocated. The TSANZ document Organ Transplantation from Deceased Donors: Consensus Statement on Eligibility Criteria and Allocation Protocols was released in version 1.1 in June 2011, version 1.2 in May 2012, and version 1.3 in January 2014; version 1.4 was released in April 2015. The current document (Clinical Guidelines for Organ Transplantation from Deceased Donors) replaces the previous Consensus Statement, and was developed by the TSANZ Advisory Committees with written feedback sought through a targeted consultation process (see Appendix B). Version 1.0 of the Clinical Guidelines was released in April 2016, with updates released in May 2017 (version 1.1), and December 2018 (version 1.2). The current document, Version 1.3, updates and replaces all prior versions of the Clinical Guidelines. Central to the eligibility criteria and allocation protocols described in this document are the following ethical principles, which are embodied in the National Health and Medical Research Council (NHMRC) publication Ethical Guidelines for Organ Transplantation from Deceased Donors (the Ethical Guidelines):1 1.
Load more

Recommended publications
  • Euro GTP Guidance
    EURO­GTP Euro GTP Guidance European Union Project in the framework of the Public Health Program Agreement number: 2007 207 Coordinator: Transplant Services Foundation 1 List of Authors ‐ Euro GTP Project Coordinator TSF ▪ Transplant Services Foundation | Spain Project Partners BISLIFE | Netherlands BTV ▪ Banca Tessuti della Regione Veneto | Italy CBC ▪ Hornhautbank Berlin Charite Universitatsmedizin | Germany EHB ▪ European Homograft Bank | Belgium ESB ▪ Euro Skin Bank | Netherlands HBM ▪ Hornhautbank München Gemeinnutzige | Germany ISS‐CNT ▪ Istituto Superiore di Sanita Centro Nazionale Trapianti | Italy KCBTiK ▪ Krajowe Centrum Bankowania Tkanek I Komórek | Poland QAMH ▪ Queen Astrid Military Hospital | Belgium REGEA ▪ Tampere Yliopisto. University of Tampere | Finland i Table of Contents PURPOSE AND SCOPE ................................................................................................................................................1 SECTION A: GENERAL REQUIREMENTS .......................................................................................................................3 A.1. PERSONNEL ............................................................................................................................................................... 3 A.2. FACILITIES AND EQUIPMENT ..................................................................................................................................... 8 A.2.1. FACILITIES, EQUIPMENT AND MATERIALS FOR RECOVERY...............................................................................
    [Show full text]
  • Medical Policy
    Medical Policy Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and is therefore subject to change. *Current Policy Effective Date: 5/1/21 (See policy history boxes for previous effective dates) Title: Composite Tissue Allotransplantation Description/Background Composite tissue allotransplantation refers to the transplantation of histologically different tissue that may include skin, connective tissue, blood vessels, muscle, bone, and nerve tissue. The procedure is also known as reconstructive transplantation. To date, primary applications of this type of transplantation have been of the hand and face (partial and full), although there are also reported cases of several other composite tissue allotransplantations, including that of the larynx, knee, and abdominal wall. The first successful partial face transplant was performed in France in 2005, and the first complete facial transplant was performed in Spain in 2010. In the United States, the first facial transplant was done in 2008 at the Cleveland Clinic; this was a near-total face transplant and included the midface, nose, and bone. The first hand transplant with short-term success occurred in 1998 in France. However, the patient failed to follow the immunosuppressive regimen, which led to graft failure and removal of the hand 29 months after transplantation. The
    [Show full text]
  • Freezing of Surplus Donated Whole Eyes in the Central Eye Bank of Iran
    RESEARCH Freezing of Surplus Donated Whole Eyes in the Central Eye Bank of Iran Use of Defrosted Corneas for Deep Anterior Lamellar Keratoplasty and Report of Postoperative Eye Bank Data Mozhgan Rezaei Kanavi, MD; Mohammad Ali Javadi, MD; Fatemeh Javadi; Tahereh Chamani, MS ABSTRACT especially when a shortage exists for fresh donor corneas for transplantation. PURPOSE: To describe the method of freezing and thaw- KEYWORDS: cornea, freezing, whole eyes, DALK, ing of donated whole eyes (DWEs), which were surplus to eye banks, thawing....................................... requirements in the Central Eye Bank of Iran (CEBI), and to report the 3-year results of using defrosted corneas in deep anterior lamellar keratoplasty (DALK) in keratoconic eyes. he Central Eye Bank of Iran (CEBI) is the METHODS: The method of freezing and thawing of only eye bank in Iran and is located in Tehran. surplus DWEs in the CEBI is described. Surplus DWEs Tissue requirements for corneal and scleral at the CEBI were disinfected, processed, and transferred T transplantation in Iran are supplied and preserved to the freezer (-70°C) for long-term preservation. In case 1 of a shortage of fresh and refrigerated corneas for DALK, by the CEBI. There has been an increasing trend in a frozen DWE was defrosted and distributed for trans- corneal transplantation in Iran, from 200 grafts in plantation either as a whole eye in moist chamber or as 1988 to 6,053 in 2012 (unpublished data). Keratoco- an excised corneoscleral disc in Eusol C at 2˚C to 8˚C. nus is the most common indication for penetrating Furthermore, eye bank data of the frozen DWEs as well 1 as postoperative eye bank reports of implementation of keratoplasty in Iran, accounting for 34.5% of cases.
    [Show full text]
  • Rapidly Growing Epstein-Barr Virus-Associated Pulmonary Lymphoma After Heart Transplantation
    Eur Respir J., 1994, 7, 612–616 Copyright ERS Journals Ltd 1994 DOI: 10.1183/09031936.94.07030612 European Respiratory Journal Printed in UK - all rights reserved ISSN 0903 - 1936 CASE REPORT Rapidly growing Epstein-Barr virus-associated pulmonary lymphoma after heart transplantation M. Schwend*, M. Tiemann**, H.H. Kreipe**, M.R. Parwaresch**, E.G. Kraatz+, G. Herrmann++, R.P. Spielmann$, J. Barth* Rapidly growing Epstein-Barr virus-associated pulmonary lymphoma after heart trans- Dept of *Internal Medicine, **Hemato- plantation. M. Schwend, M. Tiemann, H.H. Kreipe, M.R. Parwaresch, E.G. Kraatz, G. pathology, +Cardiovascular Surgery, Herrmann, R.P. Spielmann, J. Barth. ERS Journals Ltd 1994. ++Cardiology, and $Radiographic Diagnostics, ABSTRACT: There is strong evidence to show an association of Epstein-Barr virus Christian-Albrechts-University of Kiel, Kiel, Germany. (EBV) infection with the development of post-transplant lymphoproliferative dis- ease. We report the rapid development of a malignant lymphoma in a heart trans- Correspondence: J. Barth plant recipient, which occurred within less than eight weeks. I. Medizinische Universitätsklinik The diagnosis of this malignant high grade B-cell lymphoma was established by Schittenhelmstr. 12 open lung biopsy, and classified as centroblastic lymphoma of polymorphic subtype. D-24105 Kiel Immunohistochemically, the lymphoma showed reactivity with the B-cell markers Germany L-26 (CD20) and Ki-B5 and with the activation marker Ber-H2 (CD30). Furthermore, an expression of the bcl-2 oncoprotein was detected. Monoclonal JH gene rearrange- Keywords: Epstein-Barr virus ment was demonstrated by polymerase chain reaction (PCR), indicating monoclonal heart transplantation pulmonary lymphoma proliferation of B-blasts.
    [Show full text]
  • Exploring Vigilance Notification for Organs
    NOTIFY - E xploring V igilanc E n otification for o rgans , t issu E s and c E lls NOTIFY Exploring VigilancE notification for organs, tissuEs and cElls A Global Consultation e 10,00 Organised by CNT with the co-sponsorship of WHO and the participation of the EU-funded SOHO V&S Project February 7-9, 2011 NOTIFY Exploring VigilancE notification for organs, tissuEs and cElls A Global Consultation Organised by CNT with the co-sponsorship of WHO and the participation of the EU-funded SOHO V&S Project February 7-9, 2011 Cover Bologna, piazza del Nettuno (photo © giulianax – Fotolia.com) © Testi Centro Nazionale Trapianti © 2011 EDITRICE COMPOSITORI Via Stalingrado 97/2 - 40128 Bologna Tel. 051/3540111 - Fax 051/327877 [email protected] www.editricecompositori.it ISBN 978-88-7794-758-1 Index Part A Bologna Consultation Report ............................................................................................................................................7 Part B Working Group Didactic Papers ......................................................................................................................................57 (i) The Transmission of Infections ..........................................................................................................................59 (ii) The Transmission of Malignancies ....................................................................................................................79 (iii) Adverse Outcomes Associated with Characteristics, Handling and Clinical Errors
    [Show full text]
  • Vascularized Composite Allografts (Lc Cendales, Section Editor)
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Springer - Publisher Connector Curr Transpl Rep (2014) 1:173–182 DOI 10.1007/s40472-014-0025-6 VASCULARIZED COMPOSITE ALLOGRAFTS (LC CENDALES, SECTION EDITOR) Vascularized Composite Allografts: Procurement, Allocation, and Implementation Axel Rahmel Published online: 3 July 2014 # The Author(s) 2014. This article is published with open access at Springerlink.com Abstract Vascularized composite allotransplantation is a allotransplantation. In 2005, the first face transplantation was continuously evolving area of modern transplant medicine. performed in Lyon [5]; since then the number of face trans- Recently, vascularized composite allografts (VCAs) have plants has increased [6]. This special category of transplants is been formally classified as ‘organs’.Inthisreview,keyas- localized at the border between tissue and organ transplanta- pects of VCA procurement are discussed, with a special focus tion. The term composite tissue allotransplantation (CTA) on interaction with the procurement of classical solid organs. used in the past reflects that it was often considered as a In addition, options for a matching and allocation system that special type of tissue transplantation [7]. Several reports ensures VCA donor organs are allocated to the best-suited looking in-depth at limb and face transplantation made it clear recipients are looked at. Finally, the different steps needed to that vascularized composite allotransplantation is in central promote VCA transplantation in society in general and in the aspects more similar to organ than to tissue transplantation medical community in particular are highlighted. [7–12]. After careful evaluation involving the transplant com- munity and the general public, the United States Department of Health and Human Services recently published its decision Keywords Transplantation .
    [Show full text]
  • EBAA Medical Standards – October 2016
    Medical Standards These Standards have the approval of the Eye Banking Committee of the American Academy of Ophthalmology October 28, 2016 Published by: EBAA th 1015 18 Street, NW, Suite 1010, Washington, DC 20036, USA www.restoresight.org ©2016. EBAA. All rights reserved. Page 1 EBAA Medical Standards – October 2016 Table of Contents A1.000 Introduction and Purpose ..............................................................................................5 A1.100 Scope ......................................................................................................................5 B1.000 Active Membership .........................................................................................................5 B1.100 Eye Bank Inspection...............................................................................................6 B1.200 Inspections by Official Agencies ...........................................................................6 C1.000 Personnel and Governance .............................................................................................6 C1.100 Director...................................................................................................................6 C1.200 Medical Director ....................................................................................................7 C1.300 Staff Performing Eye Banking Functions ..............................................................8 C1.400 Change in Governance ...........................................................................................9
    [Show full text]
  • Ethical Issues in Living-Related Corneal Tissue Transplantation
    Viewpoint Ethical issues in living-related corneal J Med Ethics: first published as 10.1136/medethics-2018-105146 on 23 May 2019. Downloaded from tissue transplantation Joséphine Behaegel, 1,2 Sorcha Ní Dhubhghaill,1,2 Heather Draper3 1Department of Ophthalmology, ABSTRact injury, typically chemical burns, chronic inflamma- Antwerp University Hospital, The cornea was the first human solid tissue to be tion and certain genetic diseases, the limbal stem Edegem, Belgium 2 transplanted successfully, and is now a common cells may be lost and the cornea becomes vascula- Faculty of Medicine and 5 6 Health Sciences, Dept of procedure in ophthalmic surgery. The grafts come from rised and opaque, leading to blindness (figure 1). Ophthalmology, Visual Optics deceased donors. Corneal therapies are now being In such cases, standard corneal transplants fail and Visual Rehabilitation, developed that rely on tissue from living-related donors. because of the inability to maintain a healthy epithe- University of Antwerp, Wilrijk, This presents new ethical challenges for ophthalmic lium. Limbal stem cell transplantation is designed to Belgium 3Division of Health Sciences, surgeons, who have hitherto been somewhat insulated address this problem by replacing the damaged or Warwick Medical School, from debates in transplantation and donation ethics. lost limbal stem cells (LSC) and restoring the ocular University of Warwick, Coventry, This paper provides the first overview of the ethical surface, which in turn increases the success rates of United Kingdom considerations generated by ocular tissue donation subsequent sight-restoring corneal transplants.7 8 from living donors and suggests how these might Limbal stem cell donations only entail the removal Correspondence to be addressed in practice.
    [Show full text]
  • MSBCBS Prior Authorization List: Codes to Be Deleted 9/27/10
    MSBCBS Prior Authorization List: Codes to be Deleted 9/27/10 FOREHEAD FLAP WITH PRESERVATION OF VASCULAR PEDICLE (EG, AXIAL PATTERN 1 15731 FLAP) ABLATION, CRYOSURGICAL, OF FIBROADENOMA, INCLUDING ULTRASOUND 2 19105 GUIDANCE, EACH FIBROADENOMA COMPUTER-ASSISTED SURGICAL NAVIGATIONAL PROCEDURE FOR MUSCULOSKELETAL PROCEDURES, IMAGE-LESS (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY 3 20985 PROCEDURE) 4 21125 AUGMENTATION, MANDIBULAR BODY OR ANGLE; PROSTHETIC MATERIAL AUGMENTATION, MANDIBULAR BODY OR ANGLE; WITH BONE GRAFT, ONLAY OR 5 21127 INTERPOSITIONAL (INCLUDES OBTAINING AUTOGRAFT) 6 21137 REDUCTION FOREHEAD; CONTOURING ONLY REDUCTION FOREHEAD; CONTOURING AND APPLICATION OF PROSTHETIC MATERIAL 7 21138 OR BONE GRAFT (INCLUDES OBTAINING AUTOGRAFT) REDUCTION FOREHEAD; CONTOURING AND SETBACK OF ANTERIOR FRONTAL SINUS 8 21139 WALL 9 21210 GRAFT, BONE; NASAL, MAXILLARY AND MALAR AREAS (INCLUDES OBTAINING GRAFT) 10 21215 GRAFT, BONE; MANDIBLE (INCLUDES OBTAINING GRAFT) ARTHROPLASTY, TEMPOROMANDIBULAR JOINT, WITH OR WITHOUT AUTOGRAFT 11 21240 (INCLUDES OBTAINING GRAFT) 12 21740 RECONSTRUCTIVE REPAIR OF PECTUS EXCAVATUM OR CARINATUM; OPEN RECONSTRUCTION REPAIR OF PECTUS EXCAVATUM OR CARINATUM; MINIMALLY 13 21742 INVASIVE APPROACH (NUSS PROCEDURE), WITHOUT THORACOSCOPY RECONSTRUCTIVE REPAIR OF PECTUS EXCAVATUM OR CARINATUM; MINIMALLY 14 21743 INVASIVE APPROACH (NUSS PROCEDURE), WITH THORACOSCOPY EXTRACORPOREAL SHOCK WAVE, HIGH ENERGY, PERFORMED BY A PHYSICIAN, REQUIRING ANESTHESIA OTHER THAN LOCAL, INCLUDING ULTRASOUND GUIDANCE, 15 28890 INVOLVING
    [Show full text]
  • AMRITA HOSPITALS AMRITA AMRITA HOSPITALS HOSPITALS Kochi * Faridabad (Delhi NCR) Kochi * Faridabad (Delhi NCR)
    AMRITA HOSPITALS HOSPITALS AMRITA AMRITA AMRITA HOSPITALS HOSPITALS Kochi * Faridabad (Delhi NCR) Kochi * Faridabad (Delhi NCR) A Comprehensive A Comprehensive Overview Overview A Comprehensive Overview AMRITA INSTITUTE OF MEDICAL SCIENCES AIMS Ponekkara P.O. Kochi, Kerala, India 682 041 Phone: (91) 484-2801234 Fax: (91) 484-2802020 email: [email protected] website: www.amritahospitals.org Copyright@2018 AMRITA HOSPITALS Kochi * Faridabad (Delhi-NCR) A COMPREHENSIVE OVERVIEW A Comprehensive Overview Copyright © 2018 by Amrita Institute of Medical Sciences All rights reserved. No portion of this book, except for brief review, may be reproduced, stored in a retrieval system, or transmitted in any form or by any means —electronic, mechanical, photocopying, recording, or otherwise without permission of the publisher. Published by: Amrita Vishwa Vidyapeetham Amrita Institute of Medical Sciences AIMS Ponekkara P.O. Kochi, Kerala 682041 India Phone: (91) 484-2801234 Fax: (91) 484-2802020 email: [email protected] website: www.amritahospitals.org June 2018 2018 ISBN 1-879410-38-9 Amrita Institute of Medical Sciences and Research Center Kochi, Kerala INDIA AMRITA HOSPITALS KOCHI * FARIDABAD (DELHI-NCR) A COMPREHENSIVE OVERVIEW 2018 Amrita Institute of Medical Sciences and Research Center Kochi, Kerala INDIA CONTENTS Mission Statement ......................................... 04 Message From The Director ......................... 05 Our Founder and Inspiration Sri Mata Amritanandamayi Devi .................. 06 Awards and Accreditations .........................
    [Show full text]
  • CIBMTR Scientific Working Committee Research Portfolio July 1, 2018
    CIBMTR Scientific July 1, Working Committee 2018 Research Portfolio Milwaukee Campus Minneapolis Campus Medical College of Wisconsin National Marrow Donor Program/ 9200 W Wisconsin Ave, Suite Be The Match – 500 N 5th St C5500 Minneapolis, MN 55401-9959 USA Milwaukee, WI 53226 USA (763) 406-5800 (414) 805-0700 cibmtr.org CIBMTR Scientific Working Committee Research Portfolio: July 1, 2018 TABLE OF CONTENTS 1.0 OVERVIEW .................................................................................................................................................................. 1 1.1 Membership ........................................................................................................................................................... 2 1.2 Leadership .............................................................................................................................................................. 2 1.3 Productivity ............................................................................................................................................................ 3 1.4 How to Get Involved ............................................................................................................................................ 3 2.0 ACUTE LEUKEMIA WORKING COMMITTEE .................................................................................................. 6 2.1 Leadership .............................................................................................................................................................
    [Show full text]
  • Ethical Issues in Transnational Eye Banking
    REVIEW Ethical Issues in Transnational Eye Banking Dominique E. Martin, PhD, MBBS, BA (Hons),* Richard Kelly, MD, BBiomed,† Gary L. A. Jones, BSc (Econ),‡ Heather Machin, RN, MBA,§ and Graeme A. Pollock, PhD, MPH, BSc (Hons)¶ discussion of issues relating to tissue-derived products and Purpose: To review ethical issues that may arise in the setting of musculoskeletal tissue banking, rather than eye banking transnational eye banking activities, such as when exporting or specifically.2,5 As recognized in the recent World Health importing corneal tissue for transplantation. Organization (WHO) Initiative on MPHOs, which aims “to Methods: A principle-based normative analysis of potential common support the development of global consensus on guiding dilemmas in transnational eye banking activities was performed. ethical principles for the donation and management of [MPHOs],”6 a number of ethical concerns are common to Results: Transnational activities in eye banking, like those in other all MPHOs, including ocular tissues used in transplanta- fields involving procurement and use of medical products of human tion.1,7 Common concerns associated with transnational origin, may present a number of ethical issues for policy makers and movement of MPHOs include national self-sufficiency, donor professionals. Key ethical concerns include the potential impact of autonomy, equity in resource distribution, and care of donors export or import activities on self-sufficiency of corneal tissue supply and recipients.1 In this article, we briefly review several within exporting and importing countries; potential disclosure ethical issues that may be associated with transnational eye requirements when obtaining consent or authorization for ocular banking activities, using the example of importation and tissue donation when donations may be exported; and difficulties exportation of corneas for transplantation.
    [Show full text]